News | October 21, 2022
Lupin launches Paliperidone Extended-Release Tablets in US
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of US $112 million in the US
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of US $112 million in the US
Esiloc was launched at the biggest doctor engagement webinar involving more than 12,000 doctors across the country
Valbenazine Capsules had annual sales of US $781 million in the United States according to IQVIA data
Extended Phenytoin Sodium Capsules are indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
The product will be manufactured at Lupin's facility in Nagpur, India.
Amantadine Extended-Release capsules had annual sales of US $2.7 million in the United States according to IQVIA data
Subscribe To Our Newsletter & Stay Updated
